NextGen Theranostics

"Exploring the future of cancer treatment 🌐 | Precision Medicine, Oncology & Theranostics 💉 | Breaking down the science for better care 🚀 #NextGenTheranostic

[UroToday.com @urotoday]

#ACCEL trial tests actinium-225-PSMA-62 in #ProstateCancer. @Ramysaleh86 @RIMUHC1 joins @neerajaiims @huntsmancancer to discuss on UroToday. Early results show reduced xerostomia & minimal toxicity—potentially expanding radioligand options beyond Lu-177. #FullVideo > https://t.co/vajcU4bOzF

[UroToday.com @urotoday]

Exploring actinium-225 in PSMA-targeted therapy for #ProstateCancer. Michael Morris, MD @MSKCancerCenter, joins Oliver Sartor, MD @MayoClinic in this discussion highlighting the CONV01-Alpha trial, which is exploring dose optimization in both pre-Pluvicto and post-Pluvicto patients with castration-resistant disease. #WatchNow > https://t.co/L4oJute4T3

[NextGen Theranostics @NextGenTher]

@ORNLIsotopes @ORNL Insightful

[NextGen Theranostics @NextGenTher]

Impressive OS benefit with manageable toxicity. +8 months and better QoL is hard to ignore. ENZA-p pushes combo RLT into real-world relevance. Curious how it will shape guidelines.

[UroToday.com @urotoday]

Phase II ENZA-p trial explores the effect of lutetium PSMA with enzalutamide. 🔥@drlouiseemmett joins Oliver Sartor, MD @MayoClinic to discuss the ENZA-p trial: Lutetium-PSMA + enzalutamide boosts OS (HR 0.549, +8mo survival) in high-risk #mCRPC patients. ✅ Better #QoL ✅ Less fatigue ✅ Adaptive dosing keeps AEs low. Game-changer?
#WatchNow > https://t.co/QnOIHh8ER9

[NextGen Theranostics @NextGenTher]

@urotoday @drlouiseemmett @MayoClinic Impressive OS benefit with manageable toxicity. +8 months and better QoL is hard to ignore.

[NextGen Theranostics @NextGenTher]

Important topic. Post-Lu-PSMA treatment decisions in mCRPC still lack standardization.

[UroToday.com @urotoday]

Real-world data on treatment patterns after PSMA-targeted therapy in #mCRPC. Oliver Sartor, MD @MayoClinic joins @zklaassen_md @GACancerCenter to discuss findings from the #PRECISION data platform examining treatments after Lutetium-617 radioligand therapy. #WatchNow > https://t.co/zhJ1Z1966c

[NextGen Theranostics @NextGenTher]

@urotoday @MayoClinic @zklaassen_md @GACancerCenter Important topic. Post-Lu-PSMA treatment decisions in mCRPC still lack standardization.

[OHSU Radiology @OHSURadiology]

Congrats to Nuc Med Technologist/CT Hybrid Tori West for winning 1st Place Technologist Best Poster at the @SNM_MI Annual Meeting!

Her abstract, "Variability in Clinical Practice of Lutetium-177 Therapies," highlights important work in advancing nuclear medicine practices.

[NextGen Theranostics @NextGenTher]

@PeterDiamandis Nuke

[NextGen Theranostics @NextGenTher]

Big step for Tb-161. Safe, well-tolerated, delivered fast. Auger era begins.

[Michael Hofman @DrMHofman]

#VIOLET Study of Terbium-161 (161Tb) - first trial of Beta/Auger therapy. Recently presented #ASCO25. Now out in @TheLancetOncol :
https://t.co/ulOgK3K2PA

🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq)
🟣Very few side effects: 1 grade 3 lymphopenia, 1 grade 3 pain exacerbation. No grade 4. No dose delays. 🟣 Completed >6 months ahead of schedule. Thanks @Isotopia_Global for just-in-time delivery of Tb-161

Huge team involved: @ButeauJames PhD, @AzadOncology medical oncology lead, @pj_physics physics lead, @LouiseKostos PhD, @MHaskali radiochemistry, many others
🟣Funding from @PCF_Science @pros_tic @PeterMacCC @Isotopia_Global
🟣🙏patients who participated, clinical trials team, nuclear medicine team

[NextGen Theranostics @NextGenTher]

@DrMHofman @TheLancetOncol Big step for Tb-161. Safe, well-tolerated, delivered fast. Auger era begins.

[EMJ Radiology @EMJRadiology]

According to real-world data, using advanced imaging before salvage radiotherapy improves survival in recurrent prostate cancer.

Discover findings on EMJ: https://t.co/Of2dnP27sd

[Oncotarget @Oncotarget]

✅ Read a #blog summary about this #research paper #published in Volume 15: "Deep learning-based whole-body PSMA PET/CT attenuation correction utilizing Pix-2-Pix GAN."

#Summary ⬇️ https://t.co/dPi0TfPyK7

#cancer #AI #prostatecancer

[JNM @JournalofNucMed]

¹⁸F-CTT1057 is effective in detecting PSMA-positive lesions, with high patient-level sensitivity and region-level specificity. https://t.co/Xzcu4vlXFH

#NuclearMedicine #MolecularImaging #ProstateCancer @stefanofanti4 @FrancescoCeci13 @NBuffi @PilarParedesMN

[Mol Imaging Radionucl Ther @MIRTOfficial]

Superscan Appearance of 68Ga PSMA PET/CT in a Patient with Refractory Prostate Cancer
You can see the free full text of the research by Zehra Pınar Koç et al.
Link : https://t.co/LJgv6zdLxk
#PSMA #prostate #cancer

[Declan Murphy @declangmurphy]

Have really enjoyed recruiting into this trial and looking forward to the readout. Maybe #eau26??

[NextGen Theranostics @NextGenTher]

"Can we kill the bone scan?"
Bone scans lack sensitivity vs PSMA PET and no longer serve any role in prostate cancer staging or diagnosis!!
— Dr. Spratt (@DrSpratticus) | #PSMAandBeyond2025

[UroToday.com @urotoday]

Can we kill the bone scan? @DrSpratticus @caseccc presents on bone scan obsolescence in #ProstateCancer imaging. Dr. Spratt demonstrates that they fail to detect cancer with sufficient sensitivity compared to PSMA PET, having no role in diagnosis or staging across disease states. #WatchNow > https://t.co/gxxJMX6yO8 @PSMAconference #PSMAandBeyond2025

[NextGen Theranostics @NextGenTher]

@seifert_ke @SNM_MI Goodluck

[NextGen Theranostics @NextGenTher]

Impressive lineup. From PSMA to PROTACs, the field is moving fast. Each trial is reshaping what frontline and beyond could mean. Lots to watch in the coming years.

[Dra. María Natalia Gandur Quiroga @nataliagandur]

🌟🔵 Avances en mHSPC y mCRPC
👨‍⚕️ Dr. Alejo Rodríguez-Vida · #GUARDSymposium2025 @OncoAlert

🔍 Ensayos fase III destacados:

🔵 CAPItello-281: Capivasertib + abiraterona en mHSPC PTEN-deficiente
🔵 PSMAddition: ¹⁷⁷Lu-PSMA + ADT + ARPI vs SoC en mHSPC PSMA+
🔵 MEVPRO-3: Mevrometostat + enzalutamida en mHSPC
🔵 MEVPRO-2 / MEVPRO-1: Mevrometostat en mCRPC ARPI naive o post-abiraterona
🔵 RECHARGE: PROTAC (BMS-986365) vs elección del investigador en mCRPC
🔵 IDeate-Prostate01: Ifinatamab Deruxtecan vs Docetaxel en mCRPC
🔵 En todos: foco en rPFS, OS, calidad de vida y biomarcadores

🧠 Hacia una nueva generación de terapias personalizadas

@tompowles1 @ProfSyedHussain @MattGalsky @AndreaNecchi
@DrFelixGuerrero @malvarezmaestro @urbano_anido @JaviMolinaC
@Dav_Lorente @vital_hevia @AnaPlatabello1 @dperfen
@DrIacovelli @PBarataMD @Uro_Dominguez @Uro_Oncologist
@RodriguezAntona @cdanicas @drenriquegrande @Ecastromarcos @APCCC_Lugano

📌 #ProstateCancer #mHSPC #mCRPC #PSMAPET #TargetedTherapy
#OncoTwitter #UroOncology #PrecisionOncology #GU25 #GUARDSymposium2025 #APCCC25

[NextGen Theranostics @NextGenTher]

@Dx_imaging @RadiologyACR @RSNA @SNM_MI @SocietyAbdRad @PennRadiology @WinshipAtEmory @DukeRadiology @MontefioreRAD @UVARadiology Another win for PSMA PET.